communicates about risk minimisation? Viola Macoli - arini , Agency - - PowerPoint PPT Presentation

▶
communicates about risk minimisation
SMART_READER_LITE
LIVE PREVIEW

communicates about risk minimisation? Viola Macoli - arini , Agency - - PowerPoint PPT Presentation

Jan 15, 2023 24 likes •446 views

How does the EU Regulatory Network communicates about risk minimisation? Viola Macoli - arini , Agency for Medicinal Products and Medical Devices (HALMED), (Croatia) Juan Garcia-Burgos , European Medicines Agency (EMA) PCWP/HCPWP Workshop on

slide-1
SLIDE 1

An agency of the European Union

How does the EU Regulatory Network communicates about risk minimisation?

PCWP/HCPWP Workshop on risk minimisation measures - 16 September 2015 Viola Macolić-Šarinić, Agency for Medicinal Products and Medical Devices (HALMED), (Croatia) Juan Garcia-Burgos, European Medicines Agency (EMA)

slide-2
SLIDE 2

Introduction

  • New legislation in pharmacovigilance:

– Unprecedented focus on (safety) communication by regulatory authorities – Communication as a key instrument for risk minimisation – environment of enhanced openness and transparency

1

slide-3
SLIDE 3
  • Risk communication:

– part of risk assessment and risk minimisation – clear messages - right audience - right time – tailored to audiences - appropriate tools and language – always in context- benefit – always address uncertainties – use of quantitative measures – Involve users of medicines - preparation – Measure effectiveness

2

slide-4
SLIDE 4

Communicating within the EU Regulatory Network

EMA does not target individual EU patients and healthcare professionals, instead:

– Strong coordination with EU Member States – EU patients and health professionals receive clear, timely and consistent messages on the safety of their medicines – Strong collaboration with patients and healthcare professionals'’ organisations

3

slide-5
SLIDE 5

Target audiences

Communication about risk minimisation issued by regulators:

– Primary target audience: patients and healthcare professionals – Media – Health ministries, public and private health bodies – Others

4

slide-6
SLIDE 6

Information made available at central level

  • ‘Product Information’ kept up-to-date (and multilingual) for all medicines centrally authorised

– Reference source for routine minimisation measures – aligned with additional measures

  • Dear Health Care Professional Communication (DHPC)

– not published at central level

  • EMA safety communications
  • Information on Risk Management Plans

– e.g. RMP summaries

  • Information on PSURs assessment & signals

5

slide-7
SLIDE 7

EMA safety communication

Start of safety review by PRAC PRAC recommendation CHMP/CMD(h)

6

slide-8
SLIDE 8

EMA safety communication

7

slide-9
SLIDE 9

Direct healthcare professional communication (DHPC)

  • Involves both industry and regulators

– important safety information – delivered directly to individual healthcare professionals – Ask them to take actions or adapt their practices

  • Process has been streamlined – clear criteria applies
  • DHPCs agreed at EU level involve PRAC

8

slide-10
SLIDE 10

Summary of risk management plan

9

slide-11
SLIDE 11

Summary of risk management plan

10

slide-12
SLIDE 12

Input from patients, consumers and healthcare professionals

  • Individuals nominated by ‘EU Network of eligible organisations’:

− through PCWP and HCPWP − No financial support available

  • Help us in:

− Designing and adapting communication tools − Preparation of actual communication materials − Dissemination of key information timely among members

  • Excellent feedback and experience.

11

slide-13
SLIDE 13

Patient input – EMA safety communication

12

slide-14
SLIDE 14

Patient input - EMA safety communication

13

slide-15
SLIDE 15

Patient/healthcare professional input

Example: Combined Hormonal Contraceptives (CHCs)

European Society of Gynaecology European association of general practitioners European association of consumers (BEUC) European Institute of women’s health Positive feedback on pre-tested messages

14

slide-16
SLIDE 16

15

slide-17
SLIDE 17

16

slide-18
SLIDE 18

17

slide-19
SLIDE 19

18

EM A NC As HC Ps MA Hs

PRAC CHMP

MAH Patients MAH(s)

Patients Patients

HCPs HCP

DHPC and communication plan (in English) Submission of translated DHPC to the NCAs Dissemination of DHPC Implemetation of the communicated issues

Communication plan

18

slide-20
SLIDE 20

19

Challenges

  • Translation of the DHCP – timelines and collaboration with the

MAHs

  • Collaboration between MAHs to issue one DHCP
  • Dissemination of the DHCP
  • Availability of the information for HCPs and patients
  • Impact of the DHCP to clinical practice?

19

slide-21
SLIDE 21

20

NCAs need

PhV dedicated person for safety communication and strong PR team

20

slide-22
SLIDE 22

DHCP in a case of a referral

Example

21

slide-23
SLIDE 23

22

slide-24
SLIDE 24

23

slide-25
SLIDE 25

24

slide-26
SLIDE 26

25

slide-27
SLIDE 27

26

slide-28
SLIDE 28

Dissemination and availability of the DHPC

Example

27

slide-29
SLIDE 29

28

slide-30
SLIDE 30

29

Ivabradine – 2 DHPCs

E-prescription system (GP software/health database)

29

slide-31
SLIDE 31

1 . 2 .

30

slide-32
SLIDE 32

Collaboration with patient organisations

31

slide-33
SLIDE 33

32

http://www.rijetke-bolesti.hr/

Croatian patient organisation for rare diseases

32

slide-34
SLIDE 34

33

http://www.rijetke-bolesti.hr/

Croatian patient organisation for rare diseases

33

slide-35
SLIDE 35

Educational materials

Have to be approved nationally

34

slide-36
SLIDE 36

35

slide-37
SLIDE 37

36

slide-38
SLIDE 38

Other ways of communication

The theatre example

37

slide-39
SLIDE 39

38

slide-40
SLIDE 40

You should talk about and report side effects of your medicines What are side effects? Antiepileptics

39

slide-41
SLIDE 41

Questions?

40

slide-42
SLIDE 42

Thank you for your attention

Further information

Juan.Garcia@ema.europa.eu Viola.Macolic@halmed.hr

Agencija za lijekove i medicinske proizvode Ksaverska cesta 4, 10 000 Zagreb Tel.: +385 1 4884 100 (centrala) • Faks: +385 1 4884 110 E-pošta: halmed@halmed.hr www.halmed.hr